Licensing Deal

C4XD Inks Worldwide Licensing Pact With AstraZeneca Worth Up To $402 Mn To Develop & Commercialise NRF2 Activator Programme

November 29,2022 05:14 AM
- By Admin

C4X Discovery Holdings plc, a pioneering drug discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

Under the terms of the agreement, C4XD will receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront.  In addition, C4XD is eligible to receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation.

Sir Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca said: “At AstraZeneca, we are committed to transforming care in respiratory and immune-mediated disease and move beyond symptom control. Our alliance with C4XD adds an important new asset to our portfolio to push the boundaries of science by targeting underlying disease drivers to potentially modify the course of these diseases.”

Dr Clive Dix, CEO of C4XD, added: “Drug Discovery is inherently scientifically complex, and it is through our unique expertise and proprietary cutting-edge technologies that C4XD is yet again proving itself as an exemplar in this field.  NRF2 is thought to be a critical but challenging anti-inflammatory target, and I am proud of the work by our team to achieve a broad stable of intellectual property for this programme, leading to our third significant deal with a truly world-renowned industry leader.  The COPD market alone is worth close to $20 billion and rising. But, more importantly, I know that in AstraZeneca’s hands, with their scientific, technical and commercial expertise, our NRF2 Activator programme has the potential to deliver life changing treatments for the millions of patients suffering with COPD across the world.”

Inflammation is a key driver in many pathological conditions including respiratory diseases.  NRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external insults, as well as the regulation of the inflammatory response.  Targeting the NRF2 pathway to reduce inflammatory damage offers the potential for a new approach to treat a variety of inflammatory diseases such as COPD, where activation of NRF2 may help in reducing the negative effects of the oxidative stress-induced progression of the disease. Lead molecules from C4XD’s oral NRF2 Activator programme have been found to significantly activate NRF2 following oral dosing, providing anti-inflammatory and antioxidant activity.

COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.  It is a common, preventable and treatable chronic lung disease which affects men and women worldwide.  Abnormalities in the small airways of the lungs lead to a narrowing of the airways, limiting airflow in and out of the lungs and destruction of parts of the lung may be observed.  Cigarette smoking is a major risk factor for COPD, causing a high level of oxidative stress in the lungs and driving chronic inflammation as well as increased severity of infection-induced flare-ups.

C4X Discovery (C4XD) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.